抑制剂 拮抗剂 激动剂 化合物库 天然产物 中间体 药物杂质

Product Data Sheet
Product Name:
CAS No.:
Cat. No.:
MWt:
Formula:
Purity :PCI-24781783355-60-2

HY-10990397.42C21H23N3O5>98

%
Solubility:DMSO 78mg/mL Water<1.2mg/mL Ethanol <1.2mg/mL
Mechanisms: Pathways:Cell Cycle/DNA Damage; Target:HDAC
Pathways:NF-KB; Target:HDAC
gyBiological Activity:
PCI-24781 (CRA-024781) is an HDAC inhibitor with Ki of 7 M. PCI-24781 (CRA-024781) is a novelbroad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows
antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials forcancer.
References:
[1]. Bhalla S et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosisthrough NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin CancerRes. 2009 May 15;15(10):3354-65.
[][2]. Cao Yang et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects ofgy()py
doxorubicin in bone sarcoma cells CANCER CHEMOTHERAPY AND PHARMACOLOGY Volume67, Number 2, 439-446
[3]. Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J, Kiguchi K.The therapeuticeffect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.JHepatol. 2012 Jul;57(1):84-91. Epub 2012 Feb 9.
[4]. Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J.Inhibition of LSD1sensitizes glioblastoma cells to histone deacetylase inhibitors.Neuro Oncol. 2011 Aug;13(8):894-903. Epu...
Caution: Not fully tested. For research purposes only
Medchemexpress LLC
doc.guandang.net

热门文档